Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab for Prevention of Post-operative Crohn's Disease Recurrence
NCT02834754Phase 2Withdrawn
- Sponsor
- Marc Schwartz
- Start
- Dec 2018
- Primary completion
- May 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vedolizumab in Crohn's disease, sponsored by Marc Schwartz. Planned start Dec 2018; status: withdrawn.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02834754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834754.